Hochhaus A, Yan X H, Willer A, Hehlmann R, Gordon M Y, Goldman J M, Melo J V
LRF Centre for Adult Leukaemia, Department of Haematology, Royal Postgraduate Medical School, London, UK.
Leukemia. 1997 Jul;11(7):933-9. doi: 10.1038/sj.leu.2400723.
Interferon regulatory factors (IRF) 1 and 2 are DNA-binding proteins which control interferon (IFN) gene expression. IRF1 functions as an activator for IFN and IFN-inducible genes, whereas IRF2 represses the action of IRF1. Expression of the two regulatory genes is itself IFN-inducible. Because therapeutic responses of chronic myeloid leukaemia (CML) patients to IFN-alpha may be determined by intracellular levels of these two mutually antagonistic transcription factors, we have devised a competitive reverse-transcription polymerase chain reaction (RT-PCR) assay which provides an estimate of the ratio of IRF1 to IRF2 expression in a given cell population. Analysis of peripheral blood leucocytes from 25 normal individuals showed that the IRF1:IRF2 ratio varied between 1.13 and 2.30 (mean +/- s.d. 1.49 +/- 0.33). Similar values were obtained for normal bone marrow specimens, with no significant difference between CD34+ and CD34- cells. In contrast, the IRF1:IRF2 ratio in leucocytes from CML patients showed a much wider variation (0.53-5.11). Eleven out of 130 patients in chronic phase had ratios above the normal range, whereas none of the 33 blast crisis samples had a ratio >2.5. Analysis of diagnostic specimens in 59 CML patients treated subsequently with IFN-alpha showed a high IRF1:IRF2 ratio of 5.11 in one of two patients who became complete responders; all the 53 patients with minimal or no cytogenetic response had ratios below 2.5. In a separate series of 97 CML patients studied after IFN-alpha therapy a highly significant correlation was found between the IRF1:IRF2 ratio and both the cytogenetic and the molecular response (ie low concentration of BCR-ABL transcripts) to treatment: 53 out of 115 prospectively analysed samples of good cytogenetic responders had ratios above 2.0, as opposed to only 13 out of 91 samples from poor responders (P < 0.0001; chi2 test). We conclude that a high ratio of IRF1/IRF2 expression may be associated with good cytogenetic and molecular response to IFN-alpha in CML.
干扰素调节因子(IRF)1和2是控制干扰素(IFN)基因表达的DNA结合蛋白。IRF1作为IFN和IFN诱导基因的激活剂,而IRF2则抑制IRF1的作用。这两个调节基因的表达本身也受IFN诱导。由于慢性髓性白血病(CML)患者对α-干扰素的治疗反应可能由这两种相互拮抗的转录因子的细胞内水平决定,我们设计了一种竞争性逆转录聚合酶链反应(RT-PCR)检测方法,用于估计给定细胞群体中IRF1与IRF2表达的比值。对25名正常个体的外周血白细胞分析显示,IRF1:IRF2比值在1.13至2.30之间变化(平均值±标准差为1.49±0.33)。正常骨髓标本也得到了类似的值,CD34 +和CD34 -细胞之间无显著差异。相比之下,CML患者白细胞中的IRF1:IRF2比值变化范围要大得多(0.53 - 5.11)。130例慢性期患者中有11例的比值高于正常范围,而33例急变期样本中无一例比值>2.5。对59例随后接受α-干扰素治疗的CML患者诊断标本分析显示,两名完全缓解患者中的一名IRF1:IRF2比值高达5.11;所有53例细胞遗传学反应轻微或无反应的患者比值均低于2.5。在另一组97例接受α-干扰素治疗后的CML患者中发现,IRF1:IRF2比值与细胞遗传学及分子反应(即BCR-ABL转录本低浓度)对治疗均高度相关:在115例前瞻性分析的细胞遗传学反应良好的样本中,53例比值高于2.0,而91例反应不佳的样本中只有13例比值高于2.0(P < 0.0001;卡方检验)。我们得出结论,在CML中,IRF1/IRF2高表达比值可能与对α-干扰素良好的细胞遗传学及分子反应相关。